Business Wire

ROSSELL-TECHSYS

10.11.2021 18:54:04 CET | Business Wire | Press release

Share
Rossell Techsys To Build EWIS Parts for the MH-60R Platform

Rossell Techsys has been awarded a contract with Lockheed Martin to build Electrical Wire Harness and Interconnect System (EWIS) parts in support of Lockheed Martin’s MH-60R aircraft that are being supplied to the Indian Navy. Last year, India signed a USD $2.1 billion deal with the United States Government as part of its Foreign Military Sales program for the purchase of 24 Lockheed Martin anti-submarine MH-60R helicopters. The first three of these MH-60R all-weather helicopters, which can support multiple missions with state-of-the-art avionics and sensors, have been delivered to the Indian Navy and are currently undergoing pilot and crew training in the United States. The delivery of 24 helicopters will be completed in five years from the time the deal was concluded. The helicopters will be modified with a variety of "India-unique" equipment and weapons. The induction of these fourth-generation MH-60Rs is expected to further enhance the Indian Navy's three-dimensional capabilities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211110006132/en/

“We are honoured to have been selected to manufacture wire harnesses for the MH-60R, an important equipment for India. We are committed to producing high-quality parts, on time, from India, furthering India’s growing strength in manufacturing to global standards and contributing to Aatmanirbhar Bharat ,” said Mr. Prabhat Kumar Bhagvandas, Chief Executive Officer, Rossell Techsys.

As part of the contract received from Lockheed Martin, Rossell Techsys shall perform “Build to Print” (BTP) manufacture of the wire harnesses that will be installed on the MH-60R. Manufacture of these parts is being performed in the “Center of Excellence” (COE), set up by Rossell Techsys for Lockheed Martin platforms. The manufacture of parts has commenced, with the first parts having successfully undergone acceptance by Lockheed Martin. The contract shall also enable Lockheed Martin to obtain offset credits towards this platform sale.

“We are excited about the opportunity to partner with Rossell Techsys and confident of their vital capability to deliver high quality cable and harness assemblies in support of the India MRH Program and the Indian Navy,” said Hamid Salim, Vice President and General Manager, Sikorsky Maritime and Mission Systems.

About Lockheed Martin

Headquartered in Bethesda, Maryland, Lockheed Martin Corporation is a global security and aerospace company that employs approximately 114,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services.

Present in India for over three decades, Lockheed Martin is proud of its longstanding relationships and commitment to customers and partners on existing and future programs ranging from transport, maritime and fighter aircraft, to sea and land-based air and missile defence projects, as well as capabilities in civil sectors including new and renewable energy. A strategic partner and developer of sovereign industrial, workforce and enterprise capability, Lockheed Martin India’s joint ventures, apprenticeships, and founding membership of the India Innovation Growth Program underscore its conviction in Indian industry, talent and progress.

Please follow @LMNews on Twitter for the latest announcements and news across the company.

About Rossell Techsys

Rossell Techsys is the Aerospace & Defense Division of Rossell India Limited, a public listed company. It is an MSME, certified to AS9100, ISO 9001, ISO 14001, ISO 45001, ISO 27001, ISO 37001 and is also ISO 31000 and NIST 800-171 compliant. It operates from a state-of-the-art 225,000 sq. ft., LEED Gold rated facility at Bangalore, providing custom engineering and manufacturing services. Core competencies are in Electrical Wiring and Interconnect Systems (EWIS), Electronic System and Systems Integration (ESSI), Test Equipment and After Market Product Support Services.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imaging Agents23.4.2026 13:29:00 CEST | Press release

Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agentsA manganese-based MRI contrast agent could address concerns with gadolinium-based contrast agents around retention in the body, security of supply, and the environment, with mangaciclanol’s clinical development under FDA Fast Track designationThe program demonstrates GE HealthCare’s commitment to advancing novel imaging agents to address unmet patient needs GE HealthCare (Nasdaq: GEHC) today announced the first patient has been dosed in the international, multi-center Phase 2/3 LUMINA clinical trial of its manganese-based magnetic resonance imaging (MRI) contrast agent, mangaciclanol, at Mayo Clinic in Rochester, Minnesota. Mangaciclanol, if approved, could offer an alternative to – or even replace – gadolinium-based MRI contrast agents, the current standard of care. The investigational agent has been granted Fast Track designation by t

Croma Pharma Launches AI-Driven Tech Venture to Revolutionize Aesthetic Medicine via Clinicore Platform23.4.2026 13:13:00 CEST | Press release

New structure to drive AI-powered innovation and international expansion Croma Pharma has launched a strategic joint venture to accelerate the development of Clinicore, its premium digital solution for aesthetic practices. This dedicated entity will focus on scaling the next generation of the platform while ensuring full continuity for existing users. Clinicore: Elevating Practice Excellence through AI Clinicore is a specialized SaaS (Software as a Service) solution designed to optimize the daily operations of aesthetic clinics. By automating patient management, scheduling, and administrative workflows, it enables healthcare professionals to focus entirely on patient care. A core element of the new strategy is a strong focus on Artificial Intelligence. Clinicore is evolving into a smart assistant, utilizing AI-driven features for automated treatment documentation, intelligent onboarding tools, and advanced process automation. This ensures that clinics can operate at maximum efficiency

NIQ Launches Commerce Lab to Build the Data and Measurement Layer for AI-Driven Commerce23.4.2026 13:00:00 CEST | Press release

NielsenIQ (NYSE: NIQ) today announced the launch of NIQ Commerce Lab, where the company is building the technology infrastructure for AI-driven commerce. The Lab will develop the data platforms, APIs, and measurement systems that power how products are discovered, evaluated, and purchased in AI-mediated environments. This includes what the industry often refers to as agentic commerce, but extends across quick commerce, social commerce, and other emerging channels—where AI is becoming the common layer shaping how consumers navigate choices and how decisions are made in real time. AI systems are rapidly moving from supporting decisions to making them—playing an increasingly central role in how commerce operates. Their effectiveness depends on the intelligence behind them. AI is Becoming the Operating Layer of Global Commerce NIQ ensures that the intelligence behind these systems is accurate, complete, and grounded in real-world behavior—reflecting how consumers actually buy, what product

Chiesi Reports Strong FY2025 Financial and Sustainability Results and Announces Leadership Transition Highlights23.4.2026 12:10:00 CEST | Press release

Strong FY2025 financial and sustainability results; leadership transition will support continuity and long-term growth Revenue up 8.2% to €3.6bn with double-digit growth in Rare Diseases and U.S. market Air sales at €1.886bn, growing 3.9% vs. 2024 - Care sales at €904m growing 13.3% vs. 2024 - Rare sales at €906m, growing 22.3% vs. 2024 Giuseppe Accogli leaving to pursue another opportunity, Group CFO Jean-Marc Bellemin named Interim CEO while new CEO search is underway Record €885m Research & Development (R&D) investment underscores continued commitment to innovation across respiratory, rare disease and specialty care Sustainability leadership further strengthened through B Corp recertification and progress on Carbon Minimal Inhaler (CMI) innovation Chiesi Group (“Chiesi”), an international research‑focused biopharmaceutical company and certified B Corp, today announced its financial results for the year ended 31 December 2025. Chiesi reported €3.625 billion in consolidated revenues,

REPLY S.p.A.: Shareholders’ Meeting Approves the 2025 Financial Statements23.4.2026 12:05:00 CEST | Press release

Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);Group net profits of €250.9 million (€211.1 million in 2024).Approval of the proposal to distribute a dividend of €1.35 per share.Approval of the plan for the purchase and/or disposal of treasury shares. The General Shareholders’ meeting of Reply S.p.A. [EXM, STAR: REY] held today approved the Financial Statements for the financial year 2025, confirming the distribution of a gross dividend of €1.35 per share. The dividend will be paid on 20 May 2026, with dividend date set on 18 May 2026 (record date on 19 May 2026). Approval of the 2025 financial statements The Reply Group closed the 2025 financial year with a consolidated turnover of €2,483.6 million, recording a 8.0% increase compared to €2,300.5 million in 2024. Consolidated EBITDA was €467.6 million, up 13.9% compared to €410.6 million recorded for the year 2024. EBIT, from January to December, was €397.1 million, up 18.5% compared to €330.4 million recorded for

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye